Why do Great Danes live about 7 to 10 years while Chihuahuas live 16 years or more? Big dogs start aging at about the same age as small ones, but they age faster.
Today's @DogAgingProject paper in Science shows why: its the speed of DNA aging. In 894 pet dogs, the chemical tags that shift on DNA with age changed faster in big dogs, especially on jumping genes, bits of DNA that copy themselves around the genome and do damage once those tags wear off. Giant breeds lost those tags about 35% faster each year than small ones.
Breeding for size also left big dogs with high IGF-1, a growth hormone, and @loyalfordogs is going after it. Its shot lowers IGF-1 in big dogs toward small-dog levels, and the FDA agreed in 2023 that the data gives a reasonable expectation it works. A daily pill for senior dogs is also in a 1,300-dog trial.
So a big dog's short life may come from a faster aging clock, which a drug could try to slow. Neither is approved yet. If one is, it will be the first drug approved to extend lifespan in any species.
Why do small dogs live longer than large dog species, and what is the biologic basis of differences in lifespan and healthspan?
Epigenetics.
There's a lot in the methylation pattern of dogs to explain this @ScienceMagazine
science.org/doi/10.1126/scie…
Boris Djordjevic retweeted
Weekly retatrutide injections cut average weight by 25.0% at the highest dose, versus 3.9% with placebo, in adults with obesity but no diabetes. Those with knee arthritis also had less knee pain; those with sleep apnoea had fewer breathing interruptions.
agingresearch.news/p/MED-428…
🤖 Made with AI

ALT How much weight did people lose? Retatrutide reduced weight in adults with obesity. Highest retatrutide dose: 25.0%; Placebo: 3.9%. Average body weight loss over 80 weeks. Most common unwanted effects: digestive problems. 2339 adults with obesity, no diabetes · Randomised placebo-controlled trial. Peer reviewed.
Retatrutide. 28.3% weight loss. 70 pounds average. TRIUMPH-1 Phase 3, published yesterday.
Every headline says “triple agonist.” Almost none explain why the third receptor changes everything.
Ozempic and Mounjaro suppress appetite. That’s the GLP-1 and GIP part. Retatrutide adds a glucagon receptor. Glucagon doesn’t kill your hunger. It raises your resting energy expenditure. Your body burns more calories doing nothing. Two fronts: eating less AND burning more.
That’s why retatrutide posted 28.3% vs Mounjaro’s 22% vs Ozempic’s 15%. The gap is in the mechanism.
Phase 2 showed 24%. Phase 3 beat it. The high-BMI group lost 85 pounds over two years. Nearly half of all participants lost more than 30% of their body weight.
I ranked 9 drugs chasing Ozempic’s market a month ago. Retatrutide was #2. The full pipeline, with every mechanism and timeline, is below.
3 years ago, the obesity drug market was basically Ozempic.
Today, it's 9 drugs deep in late-stage. Here's what each one actually adds:
1. Foundayo: latest oral GLP-1. @US_FDA approved April 1, 2026. Injections become optional.
2. Retatrutide: 24% weight loss at 48 weeks (Phase 2). Triple agonist.
3. CagriSema: less nausea than semaglutide. NDA filed December 2025.
4. Survodutide: GLP-1 + glucagon. Cuts liver fat alongside weight.
5. Amycretin: oral weekly. GLP-1 + amylin. Phase 2.
6. Petrelintide: amylin only. Phase 2 posted March 2026.
7. Mazdutide: China approved 2026. US Phase 3 ongoing.
8. Pemvidutide: obesity + MASH dual indication.
9. Monlunabant: CB1 inverse agonist. Phase 2.
The next pharma cycle may not be Novo vs Lilly. It's shaping up as mechanism vs mechanism.
Boris Djordjevic retweeted
PSA: If you've been running out of Claude session quotas on Max tier, you're not alone. Read this.
Some insane Redditor reverse engineered the Claude binaries with MITM to find 2 bugs that could have caused cache-invalidation. Tokens that aren't cached are 10x-20x more expensive and are killing your quota.
If you're using your API keys with Claude this is even worse. This is also likely why this isn't uniform, while over 500 folks replied to me and said "me too", many (including me) didn't see this issue.
There are 2 issues that are compounded here (per Redditor, I haven't independently confirmed this) :
1s bug he found is a string replacement bug in bun that invalidates cache. Apparently this has to do with the custom @bunjavascript binary that ships with standalone Claude CLI.
The workaround there is to use Claude with `npx @anthropic-ai/claude-code`
2nd bug is worse, he claims that --resume always breaks cache. And there doesn't seem to be a workaround there, except pinning to a very old version (that will miss on tons of features)
This bug is also documented on Github and confirmed by other folks.
I won't entertain the conspiracy theories there that Anthropic "chooses" to ignore these bugs because it gets them more $$$, they are actively benefiting from everyone hitting as much cached tokens as possible, so this is absolutely a great find and it does align with my thoughts earlier.
The very sudden spike in reporting for this, the non-uniform nature (some folks are completely fine, some folks are hitting quotas after saying "hey") definitely points to a bug.
cc @trq212 @bcherny @_catwu for visibility in case this helps all of us.
Boris Djordjevic retweeted
📢 The Gemini Embedding text model (gemini-embedding-001) is now generally available in the Gemini API via Google AI Studio. It supports 100+ languages and uses Matryoshka Representation Learning for flexible output dimensions, allowing devs to scale down from 3072 dimensions.
Boris Djordjevic retweeted
Ovaries age 2.5x faster than other tissues—making them perfect models for testing anti-aging drugs.
New finding: Your longevity is predicted by when your mother hits menopause. Late maternal menopause = longer life for ALL her children.
The implications are staggering 🧵
📰New @WSJ piece by @AmyDMarcus reveals how female scientists are revolutionizing aging research
Boris Djordjevic retweeted
🚨New paper on theories of ageing
I discuss the major mechanistic theories of ageing in light of recent findings as well as the fundamental nature of the ageing process.
Theoretical work is more important than ever in biology, including in ageing.
nature.com/articles/s41556-0…
Boris Djordjevic retweeted
"Zombie cells" aren't just passive—they burn energy & disrupt your biology. 🧪
The brain may compensate for their demands by stealing energy from other functions, aging the body faster.
Hat tip to @DianaMKwon for covering how chronic stress reshapes biological age from the genome to the brain.
🔗 nature.com/articles/d41586-0…
Boris Djordjevic retweeted
NEW REVIEW: Molecules that mimic calorie restriction: metformin, rapamycin, resveratrol, spermidine, aspirin
link.springer.com/article/10…
Boris Djordjevic retweeted
Build the next generation of voice agents.
We’re hosting a 2-hour Conversational Agent Hackathon with @ExaAILabs, @NotionHQ, @lovable , @boltdotnew, @n8n_io, and @NFX.
Build a voice agent in 2 hours. Compete for $10,000s in prizes.
Boris Djordjevic retweeted
🧬 The Liquid Biopsy Truth: What $40 Billion in Cancer Screening Really Buys Us
A masterful @NewYorker investigation by @DrSidMukherjee reveals why finding cancer early isn't what we think it is.
Here's what longevity clinics don't tell you... 🧵
Boris Djordjevic retweeted
OSKM revolutionized aging research, but its risks held it back.
Now, SB000 offers a safer, single-gene alternative that delivers similar rejuvenation without triggering dangerous dedifferentiation.
👇
Boris Djordjevic retweeted
The 10 Longevity Breakthroughs of 2025 That Will Transform How We Age
📍 What you're about to read isn't science fiction.
In the first 5 months of 2025:
🧬 Gene editing cured cholesterol
🤖 AI-designed youth proteins
🐕 Dogs are getting longevity drugs
👴🏽Human age reversal trials started
Here are the 10 breakthroughs reshaping aging forever 👇






















